FDA Approves Ragwitek Sublingual Immunotherapy for Children 5-17
The US FDA has expanded the approval of Ragwitek for sublingual use to treat short ragweed pollen-induced allergic rhinitis in patients aged five through 17.
The US FDA has expanded the approval of Ragwitek for sublingual use to treat short ragweed pollen-induced allergic rhinitis in patients aged five through 17.